PI
ITCI

PFG Investments’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

PFG Investments’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-3,309
Closed -$242K – 1094
2024
Q3 		$242K Sell
3,309
-5,621
-63% -$422K 0.02% 818
2024
Q2 		$612K Sell
8,930
-4,870
-35% -$338K 0.04% 383
2024
Q1 		$955K Buy
13,800
+11,000
+393% +$756K 0.06% 339
2023
Q4 		$201K Sell
2,800
-1,600
-36% -$92K 0.04% 455
2023
Q3 		$229K Hold
4,400
– – 0.04% 426
2023
Q2 		$279K Sell
4,400
-300
-6% -$18.7K 0.05% 382
2023
Q1 		$255K Buy
+4,700
New +$227K 0.05% 383

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

PFG Investments's ITCI Position: Q4 2024 in Review

PFG Investments sold out of Intra-Cellular Therapies Inc. (ITCI) in Q4 2024, closing a stake of 3,309 shares — an estimated $242K sold.

PFG Investments first reported a position in ITCI in Q1 2023 and held it in 7 quarters. The position peaked at $955K in Q1 2024. 387 funds tracked by Wall St. Rank hold ITCI as of Q4 2024.

  • PFG Investments reported no remaining Intra-Cellular Therapies Inc. position as of Q4 2024 after selling out during the quarter.
  • PFG Investments sold 3,309 Intra-Cellular Therapies Inc. shares in Q4 2024, an estimated $242K.
  • PFG Investments first reported a position in Intra-Cellular Therapies Inc. in Q1 2023 and held it in 7 quarters.
  • PFG Investments's Intra-Cellular Therapies Inc. position peaked at $955K in Q1 2024.
  • 387 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q4 2024.

Based on PFG Investments's 13F filing for Q4 2024, filed 22 Jan 2025.